Back to Agenda
FDA Science Strategies: Purposeful Scientific Leadership to Advance Innovation and Improve Patient Outcomes
Session Chair(s)
Meghana Chalasani, MHA
Associate Director for Clinical Trial Innovation, Office of New Drugs, CDER
FDA, United States
This forum will provide an overview of FDA CDER’s Science Strategies Program. It will also provide an opportunity for stakeholders, including patients and drug developers, to share their experiences, perspectives and priorities to inform FDA’s efforts.
Learning Objective : Describe FDA Center for Drug Evaluation and Research’s Office of New Drugs' efforts to enhance therapeutic-specific strategic planning and scientific leadership; Discuss the opportunities for key stakeholders including, patients, academia, drug developers, health care providers, and payers, to help advance FDA’s therapeutic-specific science strategies.
Speaker(s)
Panelist
Klaus Romero, MD, MS
Critical Path Institute, United States
Chief Executive Officer
Panelist
Jeffrey Nahum Siegel, DrMed, MD
FDA, United States
Director, Office of Drug Evaluation Sciences, OND, CDER
Panelist
Michelle Campbell, PhD
FDA, United States
Associate Director, Stakeholder Engagement and Clinical Outcomes, ON, OND, CDER
Panelist
Meaghan Malley
ASN Alliance for Kidney Health, United States
Senior Project Associate, Kidney Health Initiative
Have an account?